More Videos
SPECIAL REPORT
MOST SHARED
- The 'Real' Jobless Rate: 17.5% Of Workers Are Unemployed
- Ritz-Carlton ?Struggling? in the US: President
- Garlic Price Rises Surpass Gold, Stocks in China
- Obama Reiterates Commitment to Boost US-India Ties
- Oil Price to Average $75.40 in 2010: Poll
- Half of Banks' Losses May Still Be Hidden: IMF Head
- Americans Ditch Planes for Trains this Thanksgiving
- New-Home Sales Jump 6.2% To Highest Level in Over Year
- Jobless Claims Below 500,000, Durable Orders Slip
- Topless Business Is Taking Off
- 3 Software Stock Picks from Lazard's Senior Analyst
- Schork Oil Outlook: Gas Bulls Pinning Hopes on Mother Nature
- Toyota Makes Recall Fix And So Long Saab
- Investors Bet on a New Year's Rally For eBay
- Why You Should Play the Reflation Trade: Stock Picker
- Citi Mortgage Reveals What Treasury Won't
- S&P to Hit 1,200 by Year-End: Chief Investor
- Amended Berkshire Hathaway Filing Indicates No Secret Stock Stakes at End of Q3
- Consumer Mood Improves, But Anxiety Over Finances
- Jobless Claims Below 500,000, Durable Orders Slip
- AIG Board OKs CEO Pay; Benmosche Agrees to Stay
- Half of Banks' Losses May Still Be Hidden: IMF Head
- Obama Going to Copenhagen Climate Summit
- Half of Banks' Losses May Still Be Hidden: IMF Head
- Seeking Deals, Holiday Fliers Get Early Start
- Americans Ditch Planes for Trains this Thanksgiving
- Oil Price to Average $75.40 in 2010: Poll
PHARMA'S MARKET VIDEO
RSS FEED
Pharma's Market
Text Size 
 |
CNBC.com |
] and a late-day rally in the stock, analysts are providing clients their take on the numbers as the shares traded lower in the early going. Deutsche Bank's Barbara Ryan is keeping her long-standing "Buy" rating on PFE, even though she told me recently she's been "long and wrong" on the stock. In a note to clients this morning, Ryan reiterates her opinion that Pfizer needs to do a big deal. "Some highly bankable revenues must be added," she writes. Nonetheless, Ryan backs up her rating by arguing (the parenthetical comments are mine), "Due to the current high dividend (nearly six percent), and the lack of financial risks to it (Pfizer is loaded with cash), we see limited downside in the shares...."
Bernstein's Tim Anderson is maintaining a "Market Perform" rating on the Dow component. He writes, "On a fundamental basis, PFE continues to look problematic. That said, in the current macroeconomic environment, PFE may represent a comparatively safe-haven and could see at least some share price appreciation."
Catherine Arnold at Credit Suisse has a "Neutral" rating on PFE. She writes, "PFE's outlook remains challenging. We believe that internal development programs are inadequate to remedy the outlook for diminishing future cash flows, and thus future acquisitions remain possible."
Barbara Ryan has repeatedly mentioned Amgen [AMGN
Loading...
()
] as a sensible takeout target for Pfizer. The biotech giant reports its earnings after the closing bell today.
The company essentially pre-announced its earnings per share earlier this month at the JPMorgan Healthcare Conference--so once again keep an eye on the sales of AMGN's embattled anemia drugs Aranesp and Epogen. And watch for commentary on the status of the company's late-stage experimental drug for osteoporosis known as D-mab.
Deutsche Bank and Bernstein make a market in PFE, own at least one percent of the shares and someone on the Bernstein research team is long PFE. Deutsche also wants to bank Pfizer. Credit Suisse has banked PFE and wants to do it again soon.
Questions? Comments?
Data is a real-time snapshot *Data is delayed at least 15 minutes